Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Sarepta Therapeutics Inc (SRPT): Why This Stock’s Shares Fell

Although we don’t believe in timing the market or panicking over market movements, we do like to keep an eye on big changes — just in case they’re material to our investing thesis.

What: Shares of Sarepta Therapeutics Inc (NASDAQ:SRPT), a biopharmaceutical company focused on RNA-based therapies, fell as much as 16% after updating its status in an attempt to gain an accelerated approval for its Duchenne muscular dystrophy drug, eteplirsen.

Sarepta Therapeutics Inc (NASDAQ:SRPT)

So what: In a press release after the bell yesterday, Sarepta Therapeutics Inc (NASDAQ:SRPT) noted that the Food and Drug Administration requested additional information about its mid-stage clinical results. Specifically, the FDA requested feedback as to why dystrophin – a protein whose production is encouraged by eteplirsen — would be an acceptable surrogate endpoint and predictor of clinical benefit in patients with DMD. The FDA also requested additional safety data relating to a potential accelerated approval filing. Research firm Leerink Swann took the opportunity to downgrade Sarepta Therapeutics Inc (NASDAQ:SRPT) to “market perform” from “outperform” on the news and lower its price target to $41 from $45 on the request for additional data.

Now what: There’s really two ways you can look at this. From a negative perspective the FDA is questioning whether there’s enough reason to believe that eteplirsen’s increased dystrophin production leads to clinical benefits for DMD patients. If Sarepta Therapeutics Inc (NASDAQ:SRPT) can’t prove this to the satisfaction of the FDA, it’ll need to run a phase 3 trial, which is both costly and time consuming. On the other hand, the glass-half-full crowd will see this as a willingness by the FDA to move eteplirsen into an accelerated approval status once Sarepta satisfies its requests. It’s a bit early to lean either way, but, if forced to choose, I’m still betting on eteplirsen eventually securing an accelerated approval.

Craving more input? Start by adding Sarepta Therapeutics Inc (NASDAQ:SRPT) to your free and personalized watchlist so you can keep up on the latest news with the company.

The article Why Sarepta Therapeutics Shares Tumbled originally appeared on

Fool contributor Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.